

Comments on Myths and Medical Tourism

By Neil Lunt



Pedro Pita Barros

Review of presentation

(based on slides and background paper)

- Medical tourism vs Health tourism/definition
- Demand side view – lack of hard data, predictions of flows of patients seem “vaporware”; different types of demand
- Supply side view – need to understand better the demand side

Review of presentation

- Matchmakers: how do demand and supply meet? – role of networks, information, travel and hospitality, quality of care, aftercare, legal issues
- Impacts on origin country and on destination country



Myth	Rated as
Myth 1 – Exponential growth	Busted – not realized; take a reality check
Myth 2 – Global market	Plausible for same types of care; but bilateral flows are more relevant than initially thought; not a level playing field
Myth 3 – Government action can help	Busted – go back to myth 1 and myth 2

Comments

- The Demand side:
- Definition of consumers – narrow definition – out-of-pocket & sick & willing to travel
- But for important procedures people want to have insurance. This changes a lot:
 - New player – the third payer
 - Changes the trade-off of staying at home for treatment and travelling for treatment
 - Who's really the key decision maker?

- In the OECD report, more types of medical tourists:
 - Temporary visitors abroad – unlucky to get sick – not medical tourism, not likely to be
 - Long term residents – not medical tourists – but create a pressure for local health systems (ex: patients treated in Portugal with type of care denied in the UK)
 - Common borders – share of facilities, not really medical tourism, “it is just the border”
 - Outsourced patients – “collective” medical tourists – the more promising in my view.

Demand side

- Key features (OECD report): “low cost treatments”, “helped by cheap flights”, “internet sources of information”
- Is this diverted demand or new demand?
Crucial to understand the dynamics and implications of policies and business decisions
- Diverted demand likely to create over-investment with no patients flow corresponding

- Medical tourism vs. cross-border care in Europe
- Basic element – people choose but payment is limited at cost/payment at home by the third party payer (public or private)
- Economic properties similar to that of reference price system in pharmaceuticals, but here product differentiation / certification / reputation can soften competition - but we need more analysis on market interactions and competitive process

Demand side

- Some attempts look at demand from Diaspora populations – how much of it can be done for Portugal? Portuguese in US & Canada (price), in Africa (lack of services), in other European countries (back-to-origins?)

Supply side

- Suppose that medical tourists are solely patients willing to pay out-of-pocket - are they in sufficient numbers and steady flow to justify investments?
- First years of global activity may reflect a stock effect and not a permanent flow a patients
- Which investments can be justified by the flow?

Supply side

- Are we talking about *de novo* investments or just additional patients to use idle capacity in the supply side?
- Target outsourced patients? Institutions can do repeated purchases, establish a valuable relationship that can be nurtured
- Minimum efficient scale to operate?
- What opportunities?

Prices in Portugal - SIGIC

	US	India	Thailand	Singapore	Malaysia	Mexico	Poland	UK	Portugal
CABG	113,000	10,000	13,000	20,000	9,000	3,250	7,140	13,921	9,527
Heart Valve Rep	150,000	9,500	11,000	13,000	9,000	18,000	9,520		15,227
Angioplasty	47,000	11,000	10,000	13,000	11,000	15,000	7,300	8,000	14,830
Hip repl	47,000	9,000	12,000	11,000	10,000	17,300	6,120	12,000	6,624
Mastectomy	17,000	7,500	9,000	12,400		7,500			2,774
Rinoplasty	4,500	2,000	2,500	4,375	2,083	3,200	1,700	3,500	1,217

Units: USD; Portugal prices based in DRG paid under the SIGIC (Sept 2012)

Market factors

- Errors, medical liability and judicial system
- How information is given?
- What information?
- What if?
 - NHS providers attempting to deal with institutions
 - NHS – to – NHS – reciprocity?

Matchmakers

- Internet: information (reliable?); patients experience and satisfaction
- Certification / accreditation – from distinctive factor to minimum threshold?
- Who are the critical decision makers?
- Economics? Can we talk about two-sided markets features?

Origin and destination

- Bear in mind that outbound from some countries need to be inbound to others
- Net income is not as important as consultants want to make believe (conflict of interest?)
- Look for general equilibrium effects – moving patients North – South – pressure on South medical labour markets, increasing wages and cost of care there, while having the reverse effect on North; but alternative is factor mobility, brain drain?

Government intervention

- Not clear where is the externality / public good / market failure requiring intervention
- Not clear where is the data to define intervention type and intensity
- Governments can be on both sides – as a payer (demand) and as a supplier / support to suppliers (supply)

Government intervention

- What if all countries try to do the same?
- No demand creation just demand diverted from other places
- No net gain but too much investment
- Different issue: what if Government institutions try to do it? No business risk (failure) for public hospitals? (Government failure in business decisions)